---
title: Amperison 0,5
image: "/uploads/amperison.jpg"
group: Hepatitis B
ingredient: Entecavir (Entecavir Monohydrat)
excipients: Lactose, polyvinyl pyrolydol K30, microcrystallin cellulose 101, croscarmellose
  sodium, magnesium stearate, aerosil, HPMC 606, HPMC 615, PEG 6000, talc, titanium
  dioxide, just enough for 1 tablet.
assign: |-
  - Treatment of chronic hepatitis B virus (HBV) in adults and children 16 years of age and older with evidence of active HBV replication resulting in a significant increase in blood DNA-HBV and persistent elevations in serum aminotransferase levels (ALT or AST) or with histological evidence of active liver disease.
  - Treatment of chronic hepatitis B virus in adults and children 16 years of age and older with liver damage and liver failure (decompensated liver disease).
expiry_date: 36 months
pack: |-
  Box of 3 blisters x 10 film coated tablets.
  Box of 10 blisters x 10 film-coated tablets.
preservation: Store in a dry place, at a temperature not exceeding 30Â°C, protected
  from light.
origin: Vietnam
amount_use: |-
  Take on an empty stomach (at least 2 hours after a meal and 2 hours before the next meal).
  The recommended dose of entecavir for adults and adolescents 16 years of age and older with chronic hepatitis B virus infection and who have not received nucleosides: 0.5 mg, taken once a day.
  The recommended dose of entecavir for adults and adolescents (16 years of age) with a history of hepatitis B virus infection while taking lamivudine or with lamivudine resistance mutations: 1mg, taken once a day.
contraindications: Patients who are sensitive to the components of the drug.
careful: |-
  CKD.
  Decompensated liver disease.
  Lactic acidosis and severe hepatomegaly with fatty liver.
  Resistance and prevention of drug resistance in patients receiving lamivudine.
  Children.
  Liver transplant recipient.
  Patients were co-infected with hepatitis C or D.
  Patients with HIV/HBV co-infection should not be treated with antiretroviral drugs.
  HIV/HBV coinfected patients were treated with antiretroviral drugs.
  Patients with galactose intolerance, Lapp lactose deficiency, glucose-galactose malabsorption.

---
